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Background. Many health care centers worldwide use the Platelia Aspergillus enzyme immunoassay (PA-EIA;
Bio-Rad Laboratories) for diagnosis of invasive aspergillosis (IA). A cutoff optical density (OD) index of 1.5 was
originally recommended by the manufacturer, but in practice, most institutions use lower cutoff values. Moreover,
a cutoff OD index of 0.5 was recently approved in the United States. In the present study, we set out to optimize
the cutoff level by performing a retrospective analysis of PA-EIA values for samples that had been obtained
prospectively from adult patients at risk for IA at 2 European health care centers.
Methods. In total, 239 treatment episodes were included of which there were 19 episodes of proven IA and
19 episodes of probable IA. Per-episode and per-test analyses and receiver operating characteristic curves were
used to determine the optimal cutoff value.
Results. In the per-episode analysis, lowering the cutoff OD index for positivity from 1.5 to 0.5 increased the
overall sensitivity by 21% (from 76.3% to 97.4%) but decreased the overall specificity by 7% (from 97.5% to
90.5%). Requiring 2 consecutive samples with an OD index 0.5 resulted in the highest test accuracy, with an
improved positive predictive value. At a cutoff OD index of 0.5, the antigen test result was positive during the
week before conventional diagnosis in 65% of cases and during the week of diagnosis in 79.5% of cases.
Conclusions. A cutoff OD index of 0.5—identical to the approved cutoff in the United States—improves the
overall performance of the PA-EIA for adult hematology patients.
Infections due to Aspergillus species are a leading cause
of morbidity and mortality among immunocompro-
mised patients, especially among patients who undergo
intensive chemotherapy for hematological malignancies
and those who undergo hematopoietic stem cell trans-
plantation [1–4]. A high crude mortality rate has been
observed; this stems, in part, from the inability to make
a timely and reliable diagnosis [5]. For this reason,
novel techniques based on the detection of specific fun-
gal antigens, such as galactomannan and b-d-glucan,
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and on the amplification of fungal DNA by PCR tech-
niques have become the focus of clinical study [6].
During the past decade, considerable experience has
been gained with the Platelia Aspergillus galactomannan
EIA (PA-EIA; Bio-Rad Laboratories), which uses the
galactofuranose-specific rat monoclonal antibody EB-
A2 to both capture and detect galactomannan [7–17].
The test has been commercially available in Europe
since the mid-1990s and was approved for diagnostic
use by the US Food and Drug Administration in 2003
[18, 19]. However, there has been a major difference
between the cutoff OD indices. In Europe, the man-
ufacturer originally recommended interpreting an op-
tical density (OD) index 1.5 as a positive result and
an OD index !1.0 as a negative result, with indices of
1.0–1.5 being indeterminate. By contrast, in the United
States, an OD index 0.5 is interpreted as a positive
result [19]. Lowering the threshold for negative samples
from 1.0 to 0.8 and for positive samples from 1.5 to
1.0 was already suggested in 1998 by Verweij et al. [20].
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Also, in practice, many European centers already use a lower
cutoff OD index of 0.5 or 0.7 to classify positive results [17,
21]. Not surprisingly, these differences may account for much
of the variation in the performance of the test, especially be-
cause lower cutoff values are likely to increase test sensitivity
at the expense of test accuracy [22, 23]. The frequency of sam-
pling may also play a role [24].
In the present study, we assessed the performance of the PA-
EIA using different cutoff OD indices. We used plasma and
serum samples that had been obtained prospectively. Contrary
to previous studies, most of which involved single health care
centers [8–16, 21], this study was able to compare the perfor-
mance (receiver operating characteristic [ROC] analysis) of the
PA-EIA at 2 health care centers that have lengthy experience
in Aspergillus antigen screening for patients who are at high
risk for the development of invasive aspergillosis (IA). Inter-
estingly, the frequency of sampling and the frequency of IA
differed significantly in both centers.
SUBJECTS, MATERIALS, AND METHODS
Patients and serum samples. The patients included in this
retrospective study were adults (age, 16 years) at high risk of
developing IA because of prolonged neutropenia that had re-
sulted from intensive chemotherapy for underlying hematologic
disorders (mainly acute leukemia/myelodysplastic syndrome)
or from myeloablative conditioning therapy to prepare for a
hematopoietic stem cell transplantation. Samples had been col-
lected from patients admitted to the University Hospital Gas-
thuisberg (Leuven, Belgium) during the period from November
2001 through July 2004 and the Radboud University Nijmegen
Medical Center (Nijmegen, The Netherlands) during the period
from January 2002 through March 2005. Both health care cen-
ters had implemented a screening program for patients at high
risk of IA. In Leuven, blood samples were tested at least twice
weekly (during November 2001–December 2002) or daily (dur-
ing January 2003–July 2004) from the start of chemotherapy
or conditioning therapy until discharge from the hospital or
death. In Nijmegen, blood samples were tested twice weekly
(on Monday and Thursday) from hospital admission until the
end of hospitalization or death. In Nijmegen, patients received
no mold-active antifungal prophylaxis, but those with oro-
pharyngeal candidiasis or gastrointestinal colonization with
Candida albicans received fluconazole (200 mg per day). In
Leuven, patients treated for acute leukemia/myelodysplastic
syndrome received prophylaxis with fluconazole (400 mg per
day), and hematopoetic stem cell transplant recipients were
given itraconazole oral solution (2.5 mg/kg twice per day).
Piperacillin-tazobactam and amoxicillin-clavulanate were not
given routinely. A diagnosis of pulmonary IA was established
using high-resolution CT and bronchoscopy with bronchoal-
veolar lavage. Therapy for proven or probable IA included both
licensed and investigational antifungal agents. The study was
approved by the Leuven and Nijmegen Institutional Review
Boards.
Patients with IA and control subjects were identified by ex-
amining microbiologic and histopathologic records, followed
by a chart review to determine the presence or absence of
proven or probable invasive fungal disease, as defined by the
European Organization for Research and Treatment of Cancer
and the National Institute of Allergy and Infectious Diseases
Mycoses Study Group [25]. In brief, patients were considered
to have proven IA if hyphae compatible with Aspergillus species
were seen in a tissue biopsy specimen or if Aspergillus species
was recovered from it. Patients were considered to have prob-
able IA if there were clinicoradiological signs and symptoms
of infection and if Aspergillus species had been seen in or re-
covered by culture of specimens obtained from the lower re-
spiratory tract (i.e., bronchoalveolar lavage, sputum, or bron-
chial aspirate). To avoid incorporation bias, detection of
circulating galactomannan was not included among the diag-
nostic criteria [26]. Possible cases of IA were excluded from
the study altogether. Demographic data, including age, sex,
underlying disease, type of transplantation, use of antifungal
prophylaxis, date of diagnosis of IA, and treatment data were
collected by chart review.
Performance of the galactomannan EIA. The amount of
galactomannan in each sample was measured using the Platelia
Aspergillus kit (Bio-Rad Laboratories) by technicians blinded
to the source of the sample and the clinical data. Plasma and
serum samples were analyzed in accordance with the manu-
facturer’s instructions [27]. In brief, 300 mL of test serum was
mixed with 100 mL of 4% EDTA treatment solution and heated
at 100C for 3 min, to dissociate immune complexes and to
precipitate any serum proteins that might interfere with the
test. Fifty mL of the supernatant was added to 50 mL of the
reaction mixture, and the 100-mL solution was added to mi-
crotitration plates precoated with the antibody EB-A2. After 90
min of incubation at 37C, the plates were washed extensively
before adding 100 mL of a substrate-chromogen solution con-
taining tetramethylbenzidine. The plates were then incubated
for another 30 min in the dark at room temperature, after
which 100 mL of 1.5 N sulfuric acid was added to stop the
reaction. The OD was read at 450/620 nm. All reagents were
purchased from Bio-Rad Laboratories. Positive and negative
controls were included in each run, as were threshold control
samples that were provided by the manufacturer. Results were
recorded as an OD index relative to the mean OD of the thresh-
old controls.
Statistical analyses. Sensitivity and specificity were calcu-
lated on both a per-episode and a per-test outcome basis. For
the per-episode calculation, each episode was classified as pos-
itive if there had ever been a positive test result, which was
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determined for a range of static cutoff OD indices (range, 0.5–
1.5) and a dynamic cutoff criterion defined by OD indices0.5
in 2 consecutive samples. Sensitivity was calculated as the pro-
portion of episodes with a diagnosis of proven and probable
IA that yielded positive test results in accordance with different
criteria. Specificity was calculated as the proportion of control
episodes that yielded negative results. Positive predictive values
and negative predictive values were also calculated. Ninety-five
percent CIs were calculated using standard methods for bi-
nominal distributions.
For the per-test analysis, each test result was interpreted as
the unit of observation [28]. As such, sensitivity was calculated
as the proportion of all test results for an episode of proven
or probable IA that yielded positive results, as determined for
a range of cutoff OD indices (range, 0.2–1.5). Conversely, spec-
ificity was the proportion of all test results for control episodes
that yielded negative results. Center-specific ROC curves were
calculated to illustrate the trade-off in rates of true-positive
results (sensitivity) versus false-positive results (1-specificity) as
the cutoff for the test was shifted from high (1.5) to low (0.2)
OD indices. A test that yields no predictive information will
generate a straight diagonal line, whereas tests that discriminate
well between 2 groups will have high rates of true-positive
results and low rates of false-positive results, yielding an ellip-
tical curve [29].
To determine the impact of shifting OD index cutoffs on the
interval between presumptive and formal diagnosis, the number
of days between the first positive test result (using 3 different
cutoffs, including 1.5, 0.5, and 20.5) and the day of formal
diagnosis (day 0, according to conventional methods) was cal-
culated for the cohort of patients with proven and probable
aspergillosis.
RESULTS
Characteristics of treatment episodes. Because a patient
could be included in the study with each subsequent cycle of
therapy, a per-episode rather than a per-patient analysis was
performed. A total of 239 treatment episodes from 203 patients
were identified for evaluation. The data set was restricted to
include only data from adult patients with proven or probable
IA (with plasma or serum samples obtained before diagnosis)
and from patients without IA (the control group). The episodes
were grouped as follows: 19 episodes of proven IA, 19 episodes
of probable IA, and 201 control episodes; the rate of true-
positive results was 15.9% (16.3% for Leuven and 15.5% for
Nijmegen). Demographic and treatment characteristics are
shown in table 1.
A total of 4884 serum samples were available; 3952 serum
samples were from Leuven (mean, 32 samples per episode; range,
4–96 samples per episode), and 932 serum samples were from
Nijmegen (mean, 8 samples per episode; range, 1–47 samples
per episode). Of these, 700 serum samples were analyzed from
19 episodes of proven IA, 480 from 19 episodes of probable IA,
and 3704 from 201 control episodes. The distribution of serum
samples per episode and per center is shown in table 1.
Performance of the PA-EIA. In the per-episode calcula-
tions, each episode was categorized according to whether any
positive test result was available. Sensitivity and specificity cal-
culations using different OD index cutoff values are shown in
table 2. The overall sensitivity to detect proven plus probable
IA increased by 21.1% (from 76.3% to 97.4%) when the OD
index value to define positivity (based on a single assay) was
decreased from 1.5 to 0.5. This shift of the OD index value
decreased the per-episode specificity by 7% (from 97.5% to
90.5%). The differences were more pronounced for the Nij-
megen center (data not shown). A lowering of the OD cutoff
for positivity from 1.5 to 0.5 resulted in a marked reduction
of 19.2% in the positive predictive value, from 85.3% (95% CI,
69.9%–95.1%) to 66.1% (95% CI, 52.2%–78.2%), whereas the
negative predictive value remained virtually unchanged, from
95.6% (95% CI, 91.8%–98.0%) to 99.4% (95% CI, 97.0%–
99.9%). By contrast, requiring 2 consecutive samples with an
OD index 0.5 to define positivity resulted in an improved
specificity and positive predictive value (97.5% [95% CI,
94.3%–99.2%] and 87.5% [95% CI, 73.2%–95.8%], respec-
tively) while maintaining an overall sensitivity of 92.1% and a
negative predictive value of 98.5% (95% CI, 95.7%–99.7%).
For the per-test analysis, each test result was interpreted as
the unit of observation. This analysis can be considered to be
a “worst case scenario,” because all of the screening tests are
included in the calculation. Per-test calculations yielded sen-
sitivities ranging from 17.8% to 31.7% and from 34.7% to
60.1% using OD index cutoff values of 1.5 and 0.5, respectively
(figure 1). Thus, when compared with the manufacturer’s orig-
inal threshold for positivity of 1.5, an OD index cutoff of 0.5
resulted in a doubling of the per-test sensitivity in both centers
without affecting the specificity of the assay.
To determine whether better performance of the assay could
be achieved by lowering the OD index cutoff to define positivity,
center-specific ROC curves were calculated; the diagnostic ac-
curacy, as given by the area under the ROC curve (AUC), was
0.843 for Leuven (95% CI, 0.825–0.861) and 0.808 for Nij-
megen (95% CI, 0.775–0.842) (figure 2A and 2B). In view of
the significantly higher mean number of serum samples ana-
lyzed in the cohort from Leuven, this data set was reanalyzed
assuming a twice-weekly sampling frequency (Monday and
Thursday), as was used at the Nijmegen health care center. This
approach reduced the total number of serum samples for the
Leuven center to 1150, but it did not alter the AUC (0.849;
95% CI, 0.817–0.880) of the ROC curve (data not shown).
In addition, an analysis was performed to determine the
effect of temporal proximity of sample collection to the day of
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No. of patients 16 19 168 203
No. of episodes 19 19 201 239
Sex
Male 11 15 94 120
Female 5 4 74 83
Age range, years 18–68 18–69 16–76 16–76
Underlying disorder or risk factor
ALL 5 1 28 34
AML 3 3 81 87
MDS 0 7 2 9
Other 1 1 33 35
Allogeneic HSCT 10 7 57 74
Leuven, Belgium, health care center
No. of samples 570 309 3073 3952
No. of samples per episode
Mean 44 45 30 32
Median (range) 40 (4–87) 36 (17–95) 27 (7–96) 28 (4–96)
Nijmegen, The Netherlands, health care center
No. of samples 130 171 631 932
No. of samples per episode
Mean 22 15 7 8
Median (range) 19 (10–44) 14 (1–45) 3 (1–47) 4 (1–47)
NOTE. Data are number of patients, unless otherwise indicated. ALL, acute lymphoblastic leukemia; AML, acute
myelogenous leukemia; HSCT, hematopoietic stem cell transplantation; MDS myelodysplastic syndrome.
conventional diagnosis (day 0); all serum specimens obtained
from day 7 before diagnosis (day 7) to day 7 after diagnosis
(day +7) were included in the analysis. The per-sample analysis
(table 3) shows that the sensitivity is better for tests performed
during the week of diagnosis, especially when using the index
cutoff value of 0.5. In addition, the AUC of the ROC curve
increased to 0.916 (95% CI, 0.879–0.953) and 0.984 (95% CI,
0.970–0.997) for samples obtained during week 1 and week
0, respectively (data from the Leuven center only).
A total of 3704 serum samples were analyzed from 201 con-
trol episodes (mean, 18.4 serum samples per episode; range,
1–96 serum samples per episode). Six serum samples (0.16%)
from the control group yielded false-positive results when using
a cutoff OD index of 1.5. After lowering the threshold for
positivity to 0.5, a total of 3682 serum samples (99.4%) tested
negative, whereas 22 serum specimens (0.6%) tested positive;
this finding was confirmed by a subsequent sample in only 6
(3%) of the control episodes.
We also estimated the time between the day of diagnosis of
IA (in accordance with European Organization for Research
and Treatment of Cancer/Mycoses Study Group criteria) and
the day of the first positive test result, using different OD indices
to define a positive result (data not shown). Overall, a lowering
of the OD index cutoff from 1.5 to 0.5 increased the interval
between presumptive and conventional diagnosis from 2 to 10
days and from 2 to 7 days in Leuven and Nijmegen, respectively.
DISCUSSION
The present analysis is based on data derived from 2 European
centers that have used the PA-EIA routinely as a screening assay
in high-risk neutropenic patients for many years. As evidenced
by the AUC of the ROC curves, the diagnostic accuracy (or
performance) of the assay was high and was identical in both
centers. Our analysis presents supportive evidence that an OD
index cutoff of 0.5—identical to the approved cutoff in the
United States—can be used reliably to define a case of probable
IA in this particular patient population. The increased accuracy
of the assay at a lower than previously recommended cutoff
(OD index,1.5) can be explained by the elimination of major
sources of bias and variation in the design and interpretation
in our study and by better knowledge about and avoidance of
causes of false-positive and false-negative assay results [24].
A high overall per-episode sensitivity of 97.4%, an acceptable
specificity of 90.5%, and a high negative predictive value of
99.4% were achieved; the per-episode positive predictive value
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Table 2. Sensitivity and specificity of the Platelia Aspergillus EIA (Bio-Rad Laboratories), according to selected cutoff optical density
(OD) indices and European Organization for Research and Treatment of Cancer/Mycoses Study Group classification of episodes of
invasive aspergillosis (IA).




of episodes tested Sensitivity, % (95% CI)
No. of episodes
with negative results/no.
of episodes tested Specificity, % (95% CI)
OD index 1.5
Proven IA 19/19 100 (85.4–100) … …
Probable IA 10/19 52.6 (28.9–75.5) … …
Overall 29/38 76.3 (59.8–88.6) … …
Control group … … 196/201 97.5 (94.3–99.2)
OD index 1.0
Proven IA 19/19 100 (85.4–100) … …
Probable IA 12/19 63.2 (38.4–83.7) … …
Overall 31/38 81.6 (65.7–92.3) … …
Control group … … 194/201 96.5 (93.0–98.6)
OD index 0.5
Proven IA 19/19 100 (85.4–100) … …
Probable IA 18/19 94.7 (74.0–99.9) … …
Overall 37/38 97.4 (86.2–99.9) … …
Control group … … 182/201 90.5 (85.6–94.2)
OD index 2  0.5
Proven IA 19/19 100 (85.4–100) … …
Probable IA 16/19 84.2 (60.4–96.6) … …
Overall 35/38 92.1 (78.6–98.3) … …
Control group … … 196/201 97.5 (94.3–99.2)
Figure 1. Health care center–specific sensitivity and specificity, from a per-test analysis, for proven and probable invasive aspergillosis at variable
static optical density index cutoffs for positivity (x-axis). Center 1, Leuven, Belgium; center 2, Nijmegen, The Netherlands.
was only 66.1%, but it increased significantly (without affecting
the other statistical parameters) to 87.5% when 2 consecutive
samples with an OD index 0.5 were required to define pos-
itivity. This latter observation is in line with previous findings
and once more underscores the importance of the demonstra-
tion of a gradual increase in the level of antigenemia, rather
than targeting a specific threshold [21]. A further lowering of
the index cutoff for positivity should be discouraged, because
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Figure 2. Receiver operating characteristic (ROC) curves graphing sen-
sitivity (true-positive results) versus 1-specificity (false-positive results)
using multiple optical density index cutoff values to define positivity. The
optical density index cutoff value decreases from high to low values as
the curves move from left to right. The performances of tests obtained
in Leuven, Belgium, and in Nijmegen, The Netherlands, are shown in
panels A and B. C, Performance of the tests obtained in Leuven while
mimicking a twice-weekly sampling frequency (identical to Nijmegen).
Diagonal lines, empirical ROC. AUC, area under the ROC curve.
Table 3. Changes in sensitivity of the Platelia Aspergillus EIA
(PA-EIA; Bio-Rad Laboratories) over time for proven and probable
invasive aspergillosis (IA), calculated according to test result at
different optical density (OD) index cutoff values.
Patient population, OD
Time to diagnosis
Week 1 Week 0
Leuven, Belgium
No. of samples 105 131
OD index cutoff value
1.5 24.8 (16.9–34.1) 42.0 (33.4–50.9)
1.0 44.8 (35.1–54.8) 58.0 (49.1–66.6)
0.5 66.7 (56.8–75.6) 84.0 (76.6–89.8)
Nijmegen, The Netherlandsa
No. of samples 35 40
OD index cutoff value
1.5 34.4 (16.8–49.3) 47.5 (31.5–63.9)
1.0 42.9 (26.3–60.6) 55.0 (38.5–70.7)
0.5 60.0 (42.1–76.1) 65.0 (48.3–79.4)
Overall
No. of samples 140 171
OD index cutoff value
1.5 26.4 (19.3–34.5) 43.3 (35.7–51.0)
1.0 44.3 (35.9–52.9) 57.3 (49.5–64.8)
0.5 65.0 (56.5–72.9) 79.5 (72.7–85.3)
NOTE. Data are percentage (95% CI) of PA-EIA–positive samples, unless
otherwise indicated. Week 1 corresponds to day 7 through day 1 before
diagnosis; week 0 corresponds to day of diagnosis through day 7 after
diagnosis.
a Includes data from 15 episodes (5 proven cases and 10 probable cases
of IA).
it would lead to an unacceptably high frequency of false-positive
test results. In addition, compared with higher cutoffs and with
conventional diagnostic methods, this lower cutoff increased
the interval between presumptive and formal diagnosis; this
finding has recently also been reported by others [18].
It has been suggested that a high sampling frequency can
bias diagnostic classification when using per-episode or per-
patient analyses [30]. Although we cannot provide a definitive
answer to the question of how often the test should be per-
formed from our analysis, figure 2A and 2C show that the
accuracy of the assay was not increased by a higher sampling
frequency than twice weekly.
In line with previous reports [20–22], we observed that the
specificity of the test—in per-episode as well as per-test anal-
ysis—remained high over a wide range of thresholds for test
positivity. In this high-risk neutropenic population, few assays
(0.6%) with false-positive results were seen when a cutoff of
0.5 was used, and overall, only 3% of the control episodes tested
repeatedly positive. This low rate of false-positive results may
simply have resulted from exclusion of children [31] and cases
of possible IA from the study, as well as from the avoidance
of antibiotics that can be associated with false-positive PA-EIA
test results, including piperacillin-tazobactam [32] and amox-
icillin-clavulanate [33]
As recently suggested by Marr et al. [28], we looked at the
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performance of the assay according to a per-test analysis and
confirmed the higher sensitivity of the PA-EIA at lower thresh-
olds. In addition, sensitivity was markedly increased when the
sample was obtained closer to the date of diagnosis, especially
when a low OD index value cutoff was used to define positivity.
In summary, the results of the present study support the use
of an OD index of 0.5 as a cutoff for positivity for the PA-EIA
when used to screen neutropenic adult patients and recipients
of allogeneic hematopoetic stem cell transplants, and this cutoff
may allow for earlier diagnosis of IA. Because it is identical to
the OD index cutoff for positivity approved by the US Food
and Drug Administration in the United States, the adoption
of a single uniform cutoff worldwide not only will contribute
to standardization of the PA-EIA, but it will also facilitate clin-
ical trials in which assay results are used as a criterion for
diagnosis.
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